JP Morgan Chase’s Global Blood Therapeutics, Inc. GBT Stock Holding History

JP Morgan Chase’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-135,000	Closed	-$10.7M	–	5869
2019 Q4	$10.7M	Buy	+135,000	New	+$8M	﹤0.01%	2061
2018 Q1	–	Sell	-42,000	Closed	-$1.65M	–	5711
2017 Q4	$1.65M	Buy	+42,000	New	+$1.57M	﹤0.01%	3428

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's GBT Position: Q4 2022 in Review

JP Morgan Chase sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 2,304,636 shares — an estimated $157M sold.

JP Morgan Chase first reported a position in GBT in Q3 2015 and held it in 29 quarters. The position peaked at $157M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

JP Morgan Chase reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
JP Morgan Chase sold 2,304,636 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $157M.
JP Morgan Chase first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 29 quarters.
JP Morgan Chase's Global Blood Therapeutics, Inc. position peaked at $157M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on JP Morgan Chase's 13F filing for Q4 2022, filed 13 Feb 2023.